Rezolute (RZLT) Non-Current Debt (2018 - 2022)

Rezolute (RZLT) posted Non-Current Debt of $14.3 million for Q1 2022, up 0.76% sequentially from $14.2 million in Q4 2021.

Rezolute (RZLT) Non-Current Debt (2018 - 2022) Analysis & Trends

Rezolute has reported Non-Current Debt for 3 years, with the latest figure at $14.3 million in Q1 2022.

Quarterly Non-Current Debt changed N/A year-over-year to $14.3 million in Q1 2022, while the trailing twelve-month figure through Mar 2022 was $14.3 million (changed N/A YoY) and the FY2021 annual result came in at $14.0 million, changed N/A from the prior year.
Non-Current Debt climbed to $14.3 million in Q1 2022 per RZLT's latest filing, from $14.2 million in the prior quarter.
Over five years, Non-Current Debt peaked at $14.3 million in Q1 2022 and troughed at $767519.0 in Q2 2018.
A 3-year average of $10.6 million and a median of $14.0 million in 2021 frame the typical range for Non-Current Debt.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	882.16 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	8.96 Bn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	546.77 Mn
10	Rezolute	442.94 Mn	442.94 Mn	-	-

Download Data